The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human body by introducing mRNA as a vaccine or therapeutic agent. This represents a rising precision medicine field with great promise for preventing and treating many intractable or genetic diseases. In addition, in vitro transcribed mRNA has achieved programmed production, which is more effective, faster in design and production, as well as more flexible and cost-effective than conventional approaches that may offer. Based on these extraordinary advantages, mRNA vaccines have the characteristics of the swiftest response to large-scale outbreaks of infectious diseases, such as the currently devastating pandemic COVID-19. It has always been the scientists’ desire to improve the stability, immunogenicity, translation efficiency, and delivery system to achieve efficient and safe delivery of mRNA. Excitingly, these scientific dreams have gradually been realized with the rapid, amazing achievements of molecular biology, RNA technology, vaccinology, and nanotechnology. In this review, we comprehensively describe mRNA-based therapeutics, including their principles, manufacture, application, effects, and shortcomings. We also highlight the importance of mRNA optimization and delivery systems in successful mRNA therapeutics and discuss the key challenges and opportunities in developing these tools into powerful and versatile tools to combat many genetic, infectious, cancer, and other refractory diseases.

Pseudomonas aeruginosa ( P. aeruginosa ) is an opportunistic Gram-negative bacterium that causes severe infection in immune-weakened individuals, especially patients with cystic fibrosis, burn wounds, cancer, or chronic obstructive pulmonary disease (COPD). Treating P. aeruginosa infection with conventional antibiotics is difficult due to its intrinsic multidrug resistance.

Extraction of phenolics from Idesia polycarpa defatted fruit residue was optimized by the maximization of the yield in total phenolics, using the response surface methodology. The optimized conditions were 50% ethanol, 5 h extraction time, 1 : 40 liquid to solid ratio, and 80°C extraction temperature. The experimental average total phenolics yield was 54.49 ± 4.26 mg/g. These antioxidant properties of phenolics were comprehensively analyzed for the first time. All the extracts not only demonstrated the significant free radical scavenging activities and metal chelating activity but also inhibited lipid, lipoprotein peroxidation and revealed reducing power activity. Ethyl acetate extraction (EAE) also inhibited mushroom tyrosinase activity and significantly increased the average skin-whitening index (L value) of the skin of C57BL/6 mice, indicating its potential use for skin hyperpigmentation in humans. The results of cell experiments showed EAE could strongly inhibit cellular tyrosinase activity, which had led to the decrease of melanogenesis in B16 mouse melanoma cells. Overall, EAE is an excellent natural antioxidant and depigmenting agent, which can be developed as a new food additive, medicine, and cosmetic.

No abstract